Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts

S. J. Kennel, R. Falcioni, J. W. Wesley

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Detailed evaluations of the microdistribution of 125I-labeled monoclonal antibodies (MoAbs) to normal tissue antigens were conducted in BALB/c mice. MoAb 273-34A, which binds to a target molecule on the lumenal surface of lung endothelial cells, localizes quickly and efficiently throughout the lung vasculature. MoAb 133-13A, which binds to an antigen on macrophage-like cells expressed in nearly equal amounts in lung, liver, and spleen, localizes most efficiently to spleen and less well to liver and lung. The microdistribution of MoAb 133-13A in liver and spleen is consistent with the antigen distribution in these organs, but in the lung a more diffuse microdistribution is observed, indicating poor access of MoAb to the antigen-positive alveolar macrophages. These findings are consistent with the hypothesis that tight endothelium (lung) represents a significant barrier to extravasation of MoAb into tissue while fenestrated (spleen) and sinusoidal (liver) endothelium are more easily penetrated. In human tumor bearing nu/nu mice, the microdistribution of MoAb to the β4 and α6 subunits of integrin was studied. These MoAbs do not cross-react with murine integrins and thus are tumor-specific in the nu/nu mouse model. Localization of 125I-labeled MoAb 450-11A, which reacts with an intercellular domain of β4 integrin, is very weak and diffuse. All MoAbs to extracellular domains (mouse 450-9D, 450-30A1, and rat 439-9B) localize well to the tumor. Microdistribution of these MoAbs in the 3 different tumors is nonuniform with heavy distribution near the blood vessels, whereas antigen distribution as determined by immunoperoxidase shows a much more uniform pattern throughout the tumors. In experiments with 125I-labeled MoAb 439-9B F(ab')2, the nonuniform pattern of distribution was not changed. Gross and microdistribution of different doses of 125I-labeled MoAb 439-9B were studied. The percent of injected dose per g of MoAb in the tumor at 48 h did not vary significantly (P > 0.1) up to a dose of 500 μg/mouse, and active MoAb was recovered in comparable amounts in the serum from animals in all doses. In contrast, the microdistribution of MoAb at the high dose was different than that at low doses. At doses up to 100 μg/mouse, a perivascular pattern was obtained, whereas at 500 μg/mouse the 125I-labeled MoAb was distributed nearly evenly throughout the tumor. These data indicate that high doses of MoAb penetrate deeply into portions of the tumor that are distant from blood vessels. These data are consistent with the hypothesis that even when MoAbs have penetrated the vessel walls, movement throughout the tumor is restricted. High doses of MoAb overcome this restriction and generate a more uniform MoAb distribution.

Original languageEnglish
Pages (from-to)1529-1536
Number of pages8
JournalCancer Research
Volume51
Issue number5
Publication statusPublished - 1991

Fingerprint

Heterografts
Monoclonal Antibodies
Lung
Neoplasms
Antigens
Spleen
Integrins
Liver
Endothelium
Vascular Tissue Neoplasms
Alveolar Macrophages
Blood Vessels
Endothelial Cells
Macrophages
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts. / Kennel, S. J.; Falcioni, R.; Wesley, J. W.

In: Cancer Research, Vol. 51, No. 5, 1991, p. 1529-1536.

Research output: Contribution to journalArticle

@article{6db4f49676a2469687692d104c4b0192,
title = "Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts",
abstract = "Detailed evaluations of the microdistribution of 125I-labeled monoclonal antibodies (MoAbs) to normal tissue antigens were conducted in BALB/c mice. MoAb 273-34A, which binds to a target molecule on the lumenal surface of lung endothelial cells, localizes quickly and efficiently throughout the lung vasculature. MoAb 133-13A, which binds to an antigen on macrophage-like cells expressed in nearly equal amounts in lung, liver, and spleen, localizes most efficiently to spleen and less well to liver and lung. The microdistribution of MoAb 133-13A in liver and spleen is consistent with the antigen distribution in these organs, but in the lung a more diffuse microdistribution is observed, indicating poor access of MoAb to the antigen-positive alveolar macrophages. These findings are consistent with the hypothesis that tight endothelium (lung) represents a significant barrier to extravasation of MoAb into tissue while fenestrated (spleen) and sinusoidal (liver) endothelium are more easily penetrated. In human tumor bearing nu/nu mice, the microdistribution of MoAb to the β4 and α6 subunits of integrin was studied. These MoAbs do not cross-react with murine integrins and thus are tumor-specific in the nu/nu mouse model. Localization of 125I-labeled MoAb 450-11A, which reacts with an intercellular domain of β4 integrin, is very weak and diffuse. All MoAbs to extracellular domains (mouse 450-9D, 450-30A1, and rat 439-9B) localize well to the tumor. Microdistribution of these MoAbs in the 3 different tumors is nonuniform with heavy distribution near the blood vessels, whereas antigen distribution as determined by immunoperoxidase shows a much more uniform pattern throughout the tumors. In experiments with 125I-labeled MoAb 439-9B F(ab')2, the nonuniform pattern of distribution was not changed. Gross and microdistribution of different doses of 125I-labeled MoAb 439-9B were studied. The percent of injected dose per g of MoAb in the tumor at 48 h did not vary significantly (P > 0.1) up to a dose of 500 μg/mouse, and active MoAb was recovered in comparable amounts in the serum from animals in all doses. In contrast, the microdistribution of MoAb at the high dose was different than that at low doses. At doses up to 100 μg/mouse, a perivascular pattern was obtained, whereas at 500 μg/mouse the 125I-labeled MoAb was distributed nearly evenly throughout the tumor. These data indicate that high doses of MoAb penetrate deeply into portions of the tumor that are distant from blood vessels. These data are consistent with the hypothesis that even when MoAbs have penetrated the vessel walls, movement throughout the tumor is restricted. High doses of MoAb overcome this restriction and generate a more uniform MoAb distribution.",
author = "Kennel, {S. J.} and R. Falcioni and Wesley, {J. W.}",
year = "1991",
language = "English",
volume = "51",
pages = "1529--1536",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumor xenografts

AU - Kennel, S. J.

AU - Falcioni, R.

AU - Wesley, J. W.

PY - 1991

Y1 - 1991

N2 - Detailed evaluations of the microdistribution of 125I-labeled monoclonal antibodies (MoAbs) to normal tissue antigens were conducted in BALB/c mice. MoAb 273-34A, which binds to a target molecule on the lumenal surface of lung endothelial cells, localizes quickly and efficiently throughout the lung vasculature. MoAb 133-13A, which binds to an antigen on macrophage-like cells expressed in nearly equal amounts in lung, liver, and spleen, localizes most efficiently to spleen and less well to liver and lung. The microdistribution of MoAb 133-13A in liver and spleen is consistent with the antigen distribution in these organs, but in the lung a more diffuse microdistribution is observed, indicating poor access of MoAb to the antigen-positive alveolar macrophages. These findings are consistent with the hypothesis that tight endothelium (lung) represents a significant barrier to extravasation of MoAb into tissue while fenestrated (spleen) and sinusoidal (liver) endothelium are more easily penetrated. In human tumor bearing nu/nu mice, the microdistribution of MoAb to the β4 and α6 subunits of integrin was studied. These MoAbs do not cross-react with murine integrins and thus are tumor-specific in the nu/nu mouse model. Localization of 125I-labeled MoAb 450-11A, which reacts with an intercellular domain of β4 integrin, is very weak and diffuse. All MoAbs to extracellular domains (mouse 450-9D, 450-30A1, and rat 439-9B) localize well to the tumor. Microdistribution of these MoAbs in the 3 different tumors is nonuniform with heavy distribution near the blood vessels, whereas antigen distribution as determined by immunoperoxidase shows a much more uniform pattern throughout the tumors. In experiments with 125I-labeled MoAb 439-9B F(ab')2, the nonuniform pattern of distribution was not changed. Gross and microdistribution of different doses of 125I-labeled MoAb 439-9B were studied. The percent of injected dose per g of MoAb in the tumor at 48 h did not vary significantly (P > 0.1) up to a dose of 500 μg/mouse, and active MoAb was recovered in comparable amounts in the serum from animals in all doses. In contrast, the microdistribution of MoAb at the high dose was different than that at low doses. At doses up to 100 μg/mouse, a perivascular pattern was obtained, whereas at 500 μg/mouse the 125I-labeled MoAb was distributed nearly evenly throughout the tumor. These data indicate that high doses of MoAb penetrate deeply into portions of the tumor that are distant from blood vessels. These data are consistent with the hypothesis that even when MoAbs have penetrated the vessel walls, movement throughout the tumor is restricted. High doses of MoAb overcome this restriction and generate a more uniform MoAb distribution.

AB - Detailed evaluations of the microdistribution of 125I-labeled monoclonal antibodies (MoAbs) to normal tissue antigens were conducted in BALB/c mice. MoAb 273-34A, which binds to a target molecule on the lumenal surface of lung endothelial cells, localizes quickly and efficiently throughout the lung vasculature. MoAb 133-13A, which binds to an antigen on macrophage-like cells expressed in nearly equal amounts in lung, liver, and spleen, localizes most efficiently to spleen and less well to liver and lung. The microdistribution of MoAb 133-13A in liver and spleen is consistent with the antigen distribution in these organs, but in the lung a more diffuse microdistribution is observed, indicating poor access of MoAb to the antigen-positive alveolar macrophages. These findings are consistent with the hypothesis that tight endothelium (lung) represents a significant barrier to extravasation of MoAb into tissue while fenestrated (spleen) and sinusoidal (liver) endothelium are more easily penetrated. In human tumor bearing nu/nu mice, the microdistribution of MoAb to the β4 and α6 subunits of integrin was studied. These MoAbs do not cross-react with murine integrins and thus are tumor-specific in the nu/nu mouse model. Localization of 125I-labeled MoAb 450-11A, which reacts with an intercellular domain of β4 integrin, is very weak and diffuse. All MoAbs to extracellular domains (mouse 450-9D, 450-30A1, and rat 439-9B) localize well to the tumor. Microdistribution of these MoAbs in the 3 different tumors is nonuniform with heavy distribution near the blood vessels, whereas antigen distribution as determined by immunoperoxidase shows a much more uniform pattern throughout the tumors. In experiments with 125I-labeled MoAb 439-9B F(ab')2, the nonuniform pattern of distribution was not changed. Gross and microdistribution of different doses of 125I-labeled MoAb 439-9B were studied. The percent of injected dose per g of MoAb in the tumor at 48 h did not vary significantly (P > 0.1) up to a dose of 500 μg/mouse, and active MoAb was recovered in comparable amounts in the serum from animals in all doses. In contrast, the microdistribution of MoAb at the high dose was different than that at low doses. At doses up to 100 μg/mouse, a perivascular pattern was obtained, whereas at 500 μg/mouse the 125I-labeled MoAb was distributed nearly evenly throughout the tumor. These data indicate that high doses of MoAb penetrate deeply into portions of the tumor that are distant from blood vessels. These data are consistent with the hypothesis that even when MoAbs have penetrated the vessel walls, movement throughout the tumor is restricted. High doses of MoAb overcome this restriction and generate a more uniform MoAb distribution.

UR - http://www.scopus.com/inward/record.url?scp=0025755464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025755464&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 1529

EP - 1536

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 5

ER -